Newbridge Financial Services Group Inc. Buys 1,570 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Newbridge Financial Services Group Inc. lifted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating) by 25.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,744 shares of the exchange traded fund’s stock after purchasing an additional 1,570 shares during the quarter. Newbridge Financial Services Group Inc.’s holdings in SPDR S&P Biotech ETF were worth $575,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Matrix Capital Management Company LP bought a new position in shares of SPDR S&P Biotech ETF during the 1st quarter valued at $188,748,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of SPDR S&P Biotech ETF by 139.4% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 2,030,000 shares of the exchange traded fund’s stock valued at $182,456,000 after buying an additional 1,182,000 shares during the period. Canada Pension Plan Investment Board increased its stake in shares of SPDR S&P Biotech ETF by 200.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 1,200,000 shares of the exchange traded fund’s stock worth $134,352,000 after purchasing an additional 800,000 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in SPDR S&P Biotech ETF by 5.3% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 767,464 shares of the exchange traded fund’s stock worth $68,980,000 after purchasing an additional 38,654 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in SPDR S&P Biotech ETF by 1,931.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 724,403 shares of the exchange traded fund’s stock valued at $65,110,000 after purchasing an additional 688,740 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

XBI traded down $2.47 during midday trading on Friday, reaching $75.62. The company had a trading volume of 695,053 shares, compared to its average volume of 13,542,846. The business has a 50-day moving average of $85.55 and a two-hundred day moving average of $80.92. SPDR S&P Biotech ETF has a 1 year low of $61.78 and a 1 year high of $134.79.

About SPDR S&P Biotech ETF

(Get Rating)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.